The enhanced type I IFN signature and the released DAMPs and cytokines in the TME after oncolysis of oncolytic VACVs can further support the priming, proliferation, clonal expansion, effector function and/or memory formation of CD8+ T-cells, enabling the anti-tumor effect of CAR T-cells (83). This evidence concerns the gene CD8A and neoplasm.